Navigation Links
Cardica Announces Fiscal 2009 First Quarter Financial Results
Date:10/28/2008

- PAS-Port(R) Proximal Anastomosis System Received 510(k) Clearance from

U.S. Food and Drug Administration (FDA) - - Development Progress Triggered $1M Milestone Payment from Cook Medical -

- Conference Call Today at 4:30 p.m. Eastern Time -

REDWOOD CITY, Calif., October 28 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today reported financial results and corporate progress for its fiscal 2009 first quarter ended September 30, 2008.

"We had an excellent quarter with the FDA clearance of our PAS-Port(R) Proximal Anastomosis System for use in coronary artery bypass graft (CABG) procedures, a pivotal event for Cardica and, we believe, the field of cardiothoracic surgery," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica. "We trained 30 surgeons in September to use the PAS-Port system, and it has been used in numerous CABG surgeries throughout the United States, including in several total connector CABG cases, in which our C-Port and PAS-Port automated systems are used to connect all bypass grafts, eliminating the need to hand sew any of the vessels."

"We continue to train physicians on the use and benefits of our C-Port(R) Distal Anastomosis Systems. We also are pleased to report that our collaborations with Cook Medical are proceeding on track, and we are looking toward the launch of the Cook Vascular Access Closure Device (CVCD) in Europe," continued Dr. Hausen.

Commercial Accomplishments

-- Received 510(k) clearance from the FDA for the PAS-Port(R) Proximal Anastomosis System in September;

-- Trained a total of 358 surgeons on the C-Port(R) Distal Anastomosis Systems since product introduction, and 30 U.S. surgeons on th
'/>"/>

SOURCE Cardica, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
2. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
3. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
4. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
5. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
6. Cardica to Present at Jefferies 2nd Annual Healthcare Conference
7. Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, ... diversified life sciences company, today announced that its stockholders ... of common stock of the Company from 1,000,000,000 to ... July 27, 2015 at the Law Offices of Nixon ... the Special Meeting, there were 480,655,929 shares of common ...
(Date:7/28/2015)... 2015 CSL Behring announced today ... for review the company,s Biologics License Application (BLA) for ... the treatment of hemophilia A. In the pivotal clinical ... Hemophilia A is a congenital bleeding disorder ... affected patients are male. People with hemophilia A may ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
(Date:7/27/2015)... ... July 27, 2015 , ... This is a professional and ... basic overview of the industry including definitions, classifications, applications and industry chain structure. ... competitive landscape analysis, and key regions development status. Development policies and plans are ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3
... Oct. 1 SoluLinK, Inc., a leader ... kits, announces the,introduction of its newest product, ... kit includes all the components for the ... kit features SoluLinK,s,patented sulfo-ChromaLink Biotin linker, a ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... focused on,endocrine therapy and oncology, today reported ... second efficacy trial of its Phase 3 ... enlargement of the,prostate, with its flagship product ...
... TOLEDO announces the launch of the FBRM® C35, ... , ... ... -- Using probe-based FBRM (Focused Beam Reflectance Measurement) ...
Cached Biology Technology:SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification. 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4Monitor Granule Growth in Process with the FBRM C35 2
(Date:7/8/2015)... Florida , July 8, 2015 ... evolving as this summer,s must have products such as wearables, ... demand as popularity for biometrics based devices continues to rapidly ... NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ) ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... newly released international study reveals that the issue of climate ... States and around the world. The surveys showed that ... more likely to point to the economy over the environment. ... as more of a national problem than a personal concern. ...
... study, scientists sampled the presence of 20 species of ... in the Adirondack Park. Calculating their occurrence at increasing ... are 36 percent more likely to occur near the ... that "human-sensitive" species were 26 percent less likely. Beyond ...
... Technology developed at The University of Nottingham has been ... first comprehensive model of a fully functioning fetal heart. ... academics in the University,s Department of Electrical and Electronic ... 2008 through the University spin-out company Monica Healthcare Ltd, ...
Cached Biology News:Global surveys show environmental concerns rank low among public concerns 2Global surveys show environmental concerns rank low among public concerns 3WCS Adirondack Park study shows exurban residences impact bird communities up to 200 meters away 2WCS Adirondack Park study shows exurban residences impact bird communities up to 200 meters away 3Nottingham technology in heart development breakthrough 2Nottingham technology in heart development breakthrough 3Nottingham technology in heart development breakthrough 4
...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
... U.S. sourced, ideal for those ... Low hemoglobin; Endotoxin: < 1.0 ... US origin; U.S. sourced, ideal ... uncompromising quality. Low hemoglobin Endotoxin: ...
NEWBORN CALF SERUM AND PLASMA...
Biology Products: